Aromatase Inhibitors are prescribed to stop breast tumors from returning.  Many women take them for 5 years, but a new study was unveiled at the American Society for Clinical Oncology conference in Chicago and published online in the New England Journal of Medicine.

The study, led by a team at Harvard Medical School, found that women who received aromatase inhibitors (AIs) for 10 years rather than five were a third less likely to have their cancer return or develop cancer in their other breast.  Approx 2,000 post-menopausal women with early-stage breast cancer took part in the study.